Eli Lilly to buy HBM Healthcare portfolio company Curevo for up to USD 1.5 billion

Eli Lilly

Eli Lilly

LLY

0.00
  • Eli Lilly agreed to acquire Curevo Vaccine for up to USD 1.5 billion, split between an upfront payment and a milestone-based payment.
  • HBM Healthcare Investments holds about a 4.8% stake, built from a USD 13.3 million Series B investment in March 2025.
  • The deal is expected to lift HBM’s NAV per share by about CHF 4 (+1.4%).
  • Curevo’s lead asset is amezosvatein, a non-mRNA vaccine candidate aimed at preventing shingles.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2333550_en) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.